Overall, our data suggest that non-tumor-suppressed innate immune cells can exert robust anti-tumor effects on BTICs by inducing Gas1, providing future impetus to search for innate immune cell stimulators that can be used therapeutically to combat gliomas. This evidence concerns the gene GAS1 and neoplasm.